Monitoring Bivalirudin on Extracorporeal Pump
Monitor bivalirudin using aPTT with a target of 1.5–2 times the upper limit of normal, which is the same target range used for unfractionated heparin. 1
Primary Monitoring Parameter
Use aPTT as your primary monitoring test for bivalirudin during ECMO support 1. The 2023 ISTH guidelines explicitly recommend aPTT-based monitoring as the standard approach. This represents the most practical and widely available option for most institutions.
Target Range
- aPTT: 1.5–2 times the upper limit of normal (same as UFH targets) 1
- This typically translates to approximately 60-90 seconds in most laboratories 2
Alternative Monitoring Methods
If baseline aPTT levels are abnormal or unreliable, consider these alternatives:
- Dilute thrombin time (dTT): Can be used when aPTT is unreliable 1
- Bivalirudin-calibrated dilute thrombin time (Bival dTT): Shows excellent correlation with bivalirudin effect (R² = 0.86-0.87) and superior reliability compared to aPTT 3
- Chromogenic anti-IIa testing: Alternative option if institutional protocols exist 1
Critical Caveat About aPTT Reliability
Recent pediatric data reveals that aPTT correlates poorly with actual bivalirudin anticoagulant effect (R² = 0.004-0.1) in ECMO/VAD patients 3. Despite this limitation, aPTT remains the guideline-recommended standard because it's universally available and institutions lack validated alternatives. If your institution has access to drug-calibrated dTT assays, these provide more reliable monitoring 3.
Monitoring Frequency
While guidelines don't specify exact timing intervals, clinical practice data suggests:
- Initial 24 hours: Frequent monitoring (every 2-4 hours) until therapeutic range achieved 2
- After stabilization: Every 4-6 hours or per institutional protocol
- After dose adjustments: Recheck within 2-4 hours
- Most patients achieve therapeutic targets within the first 24 hours 2
Dosing Parameters for Context
Understanding the dosing helps frame monitoring expectations:
- Starting infusion rate: 0.02–0.05 mg/kg/min (no bolus for ECMO) 1
- Target: aPTT 1.5–2 times normal
- Dose adjustments: Titrate based on aPTT response
- Clinical experience shows patients require an average of 0.27 ± 0.37 mg/kg/h 4
Special Populations Requiring Lower Doses
- Postcardiotomy patients: Start at lower end of range 1
- Renal impairment: Significantly reduced doses (0.15 ± 0.06 mg/kg/h with CRRT vs 0.28 ± 0.36 mg/kg/h without) 4
Additional Monitoring Considerations
Heparin-like effect detection: Up to 39% of ECMO patients may have detectable heparin-like substances that interfere with aPTT 5. Consider:
- aPTT with heparinase (HPTT): Removes heparin interference
- ROTEM HEPTEM: Thromboelastometry with heparinase shows strong correlation with HPTT 5
Supplementary markers when monitoring results conflict:
- Thrombin-antithrombin complex (TAT): Reflects coagulation activation 6
- Fibrin degradation products: Assists when primary parameters are discordant 6
Critical Pitfalls to Avoid
Don't use ACT as primary monitor: ACT is mentioned in FDA labeling for PCI 7 but is unreliable for ECMO bivalirudin monitoring. Bedside ACT may not reflect true anticoagulation status 6
Don't assume aPTT reliability: While it's the recommended standard, recognize its limitations. When aPTT results don't match clinical picture, consider alternative assays 3
Don't use PCI dosing: FDA-approved PCI doses (1.75 mg/kg/h) 7 are 35-87 times higher than ECMO doses. ECMO requires 0.02-0.05 mg/kg/min (1.2-3 mg/kg/h maximum) 1
Expect time in therapeutic range around 66%: Clinical data shows patients spend approximately two-thirds of time within target aPTT range 2, so don't overreact to isolated out-of-range values
Institutional Protocol Requirement
The guidelines strongly recommend using institutionalized protocols for bivalirudin dosing and monitoring 1. This is not optional—bivalirudin management during ECMO is complex enough that ad hoc approaches increase risk of complications. If your institution lacks a protocol, develop one before routine use.